NEW YORK, July 21, 2017 /PRNewswire/ --
If you want a Stock Review on AUPH, ESPR, PRTK, or VSTM then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. Focus is on the Biotech industry, which broadly segments into the medical and agricultural markets. Although enterprising biotechnology is also being applied
Victoria, Canada headquartered Aurinia Pharmaceuticals Inc.'s shares dropped 2.65%, closing Thursday's trading session at $6.60. The stock recorded a trading volume of 1.44 million shares. The Company's shares have skyrocketed 214.29% since the start of this year. The stock is trading 0.83% above its 50-day moving average and 33.09% above its 200-day moving average. Additionally, shares of Aurinia Pharma, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada, have a Relative Strength Index (RSI) of 50.79.
On June 22nd, 2017, Aurinia Pharma announced that the six incumbent directors of the Company were elected at its annual general meeting held last June 21st, 2017. The six directors are Richard Glickman, Benjamin Rovinski, David Jayne, Hyuek Joon Lee, Lorin Randall, and George Milne. Voting results on all matters voted on at the meeting are filed on SEDAR website and EDGAR website. See our free and comprehensive research report on AUPH at:
On Thursday, shares in Ann Arbor, Michigan headquartered Esperion Therapeutics Inc. recorded a trading volume of 783,580 shares, which was above their three months average volume of 681,270 shares. The stock edged 5.63% higher, ending the day at $48.80. The Company's shares have surged 41.82% in the past month, 30.55% in the previous three months, and 289.78% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 24.46% and 93.22%, respectively. Furthermore, shares of Esperion Therapeutics have an RSI of 66.51.
On June 26th, 2017, Esperion Therapeutics announced the US Food and Drug Administration (FDA) recently confirmed the regulatory pathway to approval for the once-daily, oral-combination pill of bempedoic acid 180 mg and ezetimibe 10 mg. Based on feedback received from the FDA, the Company plans to initiate a single, global pivotal Phase-3 bridging study (1002FDC-053) for the bempedoic acid / ezetimibe combination pill that will be conducted concurrently with the ongoing global pivotal Phase-3 program for bempedoic acid.
On July 11th, 2017, research firm Jefferies initiated a 'Hold' rating on the Company's stock. ESPR free research report is just a click away at:
Boston, Massachusetts headquartered Paratek Pharmaceuticals Inc.'s stock finished the day 2.44% lower at $22.00. A total volume of 1.20 million shares was traded, which was above their three months average volume of 661,410 shares. The Company's shares have advanced 1.85% in the previous three months and 42.86% on an YTD basis. The stock is trading above its 200-day moving average by 26.65%. Additionally, shares of Paratek Pharma have an RSI of 40.30.
On July 19th, 2017, Paratek Pharma announced that it will host a conference call and live audio webcast on August 02nd , 2017, at 8:30 a.m. ET to report Q2 2017 financial results and provide an update on its clinical development efforts for omadacycline for skin infections, community-acquired bacterial pneumonia, and urinary tract infections. The audio webcast can be accessed under the Investor Relations section of the Company's website. Sign up for your complimentary report on PRTK at:
Shares in Needham, Massachusetts headquartered Verastem Inc. ended yesterday's session 2.33% higher at $3.51. The stock recorded a trading volume of 1.37 million shares, which was above its three months average volume of 892,300 shares. The Company's shares have advanced 61.01% in the last one month, 83.77% over the previous three months, and 213.39% since the start of this year. The stock is trading 38.39% and 109.40% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Verastem, which focuses on discovering and developing drugs for the treatment of cancer, have an RSI of 61.22.
On July 11th, 2017, Verastem announced the appointment of Julie B. Feder as CFO. Ms. Feder joins the Company from the Clinton Health Access Initiative, Inc. (CHAI), where she served as CFO for six years. At CHAI, Ms. Feder was responsible for managing a global team across multiple departments, and developed the global finance strategy and internal audit, treasury, and global payroll functions. Register for free on DailyStockTracker.com and download the latest research report on VSTM at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...View All